ABSTRACT
Current therapy of pulmonary arterial hypertension (PAH) addresses the pulmonary vascular tone; however, the key mechanisms like dysregulated proliferation and apoptosis as well as metabolic changes remain open. This chapter addresses current ideas on how future treatment of PAH beyond pulmonary vascular dilatation can look. We highlight epigenetic mechanisms, receptor tyrosine kinases, and transcription factors as potential targets for treatment of PAH.
